PFM Health Sciences
PFM Health Sciences reported 79 stocks worth $936M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ASND (5.6%), AXSM (4.4%) and UTHR (4.0%). Compared with Q2 2026, the fund opened new positions in SPY, CNMD and TEVA, added to AXSM, UTHR and THC, trimmed ASND, LLY and NBIX and sold out of PEN, SYK and MTD.
Latest filing: what PFM Health Sciences did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() ASND Ascendis Pharma A/s | $52.1M | 5.6% | 229K | −4,303 (−2%) | 2 of 8 | |
| 2 | ![]() AXSM Axsome Therapeutics Inc | $41M | 4.4% | 222K | +2,506 (+1%) | 8 of 8 | |
| 3 | ![]() UTHR United Therapeutics Corp Del | $37.5M | 4.0% | 69K | +19K (+39%) | 7 of 8 | |
| 4 | ![]() THC Tenet Healthcare Corp | $32.5M | 3.5% | 127K | +722 (+1%) | 8 of 8 | |
| 5 | ![]() INBX Inhibrx Biosciences Inc | $32.1M | 3.4% | 320K | +12K (+4%) | 8 of 8 | |
| 6 | ![]() LLY Eli Lilly & Co | $29M | 3.1% | 25K | −14K (−36%) | 8 of 8 | |
| 7 | ![]() NBIX Neurocrine Biosciences Inc | $29M | 3.1% | 204K | −9,071 (−4%) | 7 of 8 | |
| 8 | ![]() INDV Indivior PLC | $26.6M | 2.8% | 742K | +341K (+85%) | 3 of 8 | |
| 9 | ![]() SPY Spdr S&P 500 ETF TR | $24.7M | 2.6% | 32K | New position | 4 of 8 | |
| 10 | ![]() BBIO Bridgebio Pharma Inc | $24.1M | 2.6% | 366K | +112K (+44%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() PEN Penumbra Inc | $19M | 60K |
![]() SYK Stryker Corporation | $17.8M | 57K |
![]() MTD Mettler Toledo International | $17M | 13K |
![]() MRK Merck & Co Inc | $16.3M | 127K |
![]() LNTH Lantheus Hldgs Inc | $16.2M | 146K |
🔒 Free account: see all 30.
Options
valued at the underlying sharesReported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →PFM Health Sciences 13F FAQ
What does PFM Health Sciences own?
PFM Health Sciences reported 79 stocks worth $936M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ASND (5.6%), AXSM (4.4%) and UTHR (4.0%). The table above lists every position in the filing (the top 10 without an account).
What did PFM Health Sciences buy and sell in Q3 2026?
Compared with Q2 2026: 22 new positions, 26 added to, 29 trimmed and 39 sold out. New positions include SPY, CNMD and TEVA. It sold all of PEN, SYK and MTD.
When will PFM Health Sciences file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is PFM Health Sciences's portfolio worth?
The Q3 2026 filing reports $936M in US stocks ($1B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.



























